Ezetimibe plus simvastatin lowered lipid levels more than simvastatin monotherapy in primary hypercholesterolemia

Goldberg, A.C.
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p16
Academic Journal
The article reports that ezetimibe plus simvastatin lowered lipid levels more than simvastatin monotherapy in primary hypercholesterolemia. Mean percentage change from baseline in lipid levels and adverse events. The pooled ezetimibe plus simvastatin group had greater reductions in LDL-C, total cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B levels than the pooled simvastatin monotherapy group. In patients with primary hypercholesterolemia, ezetimibe plus simvastatin was more effective than simvastatin monotherapy for improving lipid levels and had a similar overall safety and tolerability profile.


Related Articles

  • Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density- lipoprotein cholesterol goals in a usual care setting. Bullano, Michael F.; Kamat, Siddhesh; Wertz, Debra A.; Borok, Gerald M.; Gandhi, Sanjay K.; McDonough, Kenneth L.; Willey, Vincent J. // American Journal of Health-System Pharmacy;2/1/2007, Vol. 64 Issue 3, p276 

    Purpose. The effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein (LDL) cholesterol goals in patients treated in a usual care setting was studied. Methods. Electronic medical and pharmacy administrative claims from a western U.S. health...

  • atorvastatin.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p209 

    A definition of the medical term "atorvastatin," which refers to a lipid-lowering drug used to treat elevated serum cholesterol and LDL cholesterol levels, is presented.

  • Baseline plasma plant sterol concentrations do not predict changes in serum lipids, C-reactive protein (CRP) and plasma plant sterols following intake of a plant sterol-enriched food. Houweling, A. H.; Vanstone, C. A.; Trautwein, E. A.; Duchateau, G. S. M. J. E.; Jones, P. J. H. // European Journal of Clinical Nutrition;Apr2009, Vol. 63 Issue 4, p543 

    Background/Objectives:Plant sterol (PS) consumption lowers serum cholesterol levels, while modestly increasing plasma PS concentrations. Plasma PS concentrations may reflect sterol absorption, thus individuals with high plasma plant sterol (HPS) concentrations may show greater changes in...

  • The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats. Refaie, Fawzia M.; Esmat, Amr Y.; Gawad, Soad M. Abdel; Ibrahim, Aida M.; Mohamed, Mona A. // Lipids in Health & Disease;2005, Vol. 4, p22 

    In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic (single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2 halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H) quinazolinone) at a...

  • Failure to Report Financial Disclosure Information. Ganda, Om P. // JAMA: Journal of the American Medical Association;10/6/2015, Vol. 314 Issue 13, p1404 

    A letter to the editor is presented in response to the article "Clinician understanding of cholesterol treatment guidelines," by T. C. Lee and E. G. McDonald in the 2015 issue.

  • Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults--United States, 2005-2012. Mercado, Carla; DeSimone, Ariadne K.; Odom, Erika; Gillespie, Cathleen; Ayala, Carma; Loustalot, Fleetwood // MMWR: Morbidity & Mortality Weekly Report;12/4/2015, Vol. 64 Issue 47, p1305 

    A high blood level of low-density lipoprotein cholesterol (LDL-C) remains a major risk factor for atherosclerotic cardiovascular disease (ASCVD), although data from 2005 through 2012 has shown a decline in high cholesterol (total and LDL cholesterol) along with an increase in the use of...

  • Colesevelam: A Review of its Use in Hypercholesterolemia. Robinson, Dean M.; Keating, Gillian M. // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 6, p453 

    Colesevelam hydrochloride (Cholestagel®, WelChol®) is an orally administered, non-absorbable, polymeric, bile-acid-binding agent with a higher affinity for glycocholic acid in vitro and greater capacity for binding bile acids in vivo than other bile-acid-binding agents. In randomized...

  • Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial. Kassis, Amira N.; Jones, Peter J. H. // Lipids in Health & Disease;2008, Vol. 7, Special section p1 

    Background: Sugar cane policosanols (SCP) have been shown to exert cholesterol -modulating properties in various studies conducted in Cuba by substantially reducing cholesterol synthesis. Independent research examining changes in cholesterol kinetics in response to SCP is limited to few studies,...

  • Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. Monkman; Primatesta, Paola; Poulter, Neil R // BMJ: British Medical Journal (International Edition);11/25/2000, Vol. 321 Issue 7272, p1322 

    Objective: To evaluate the prevalence of the use of lipid lowering agents and its relation to blood lipid concentrations in English adults.Design: Cross sectional survey.Setting: England, 1998.Participants: Nationally representative sample of 13 586 adults (aged 16 years) living in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics